This study tests whether adding ramucirumab to the standard drug osimertinib can delay cancer growth in people with advanced EGFR-mutant non-small cell lung cancer. About 160 participants who have not had prior targeted therapy will be randomly assigned to receive either the comb…
Phase: PHASE2 • Sponsor: Xiuning Le • Aim: Disease control
Last updated May 17, 2026 02:06 UTC